News

Newron picks up Neuronova AB
Enlarge image

BusinessItalySweden

Newron picks up Neuronova AB

14.06.2012 - Italian neuroscience specialist Newron Pharmaceuticals S.p.A. acquires the Stockholm-based Neuronova AB in a deal worth €15.4m

Bresso/Stockholm – The transaction will add two new Phase II compounds from NeuroNova to Newron’s CNS portfolio. sNN0031 is a novel drug candidate for the treatment of moderate to severe stage Parkinson’s disease (PD) that is designed to act on neural stem and progenitor cells in the brain. In a Phase I/II trial in patients with PD, the active ingredient platelet-derived growth factor BB demonstrated preliminary beneficial effects on biochemical markers of the degenerating dopamine system in PD patients. The second compound, sNN0029 with the active ingredient vascular endothelial growth factor, is intended for the treatment of amyotrophic lateral sclerosis (ALS) and is currently evaluated in a Phase I/II trial.

At the transaction close, Newron will benefit by cash and commitments of up to €16m. These funds are sufficient to provide for a Phase II study in PD as well as the ongoing Phase I/II study in ALS, in addition to the related corporate operations. The biggest investors in Neuronova, Investor and Healthcap, will also take a stake in Newron. Both will send a representative to the Milan-based company’s board of directors. At closing of the deal, the Neuronova shareholders will represent a holding of 33% in Newron’s share capital. For them, the transaction is a bid on the positive development of NeuroNova’s  compounds. “We value Newron’s expertise in taking compounds from clinical stages to regulatory filing, and support the concept of building a European CNS player that could benefit both patients and our stakeholders”, stated Jakob Lindberg from Investor. “It is the logical next step to NeuroNova to combine our advanced pipeline and know-how, originally stemming from research at Karolinska Institute and developed by our team in the recent years, with a larger player in the CNS field”, added Ulf Ljungberg, President and CEO of NeuroNova, stating that the combined product portfolio represents “a strong platform on which to build the critical mass this industry is looking for.” 

http://www.european-biotechnology-news.com/news/news/2012-02/newron-picks-up-neuronova-ab.html

R&DUKIreland

29.07.2016 GlaxoSmithKline has in-licensed Janssen’s anti-IL-33R monoclonal antibody for severe asthma. The British drugmaker is paying €208m up front for the mAb.

ResearchEUUK

27.07.2016 In view of the Brexit, research academies across Britain are calling for a “bold commitment” from the government. The Royal Society President urges the UK government to underwrite the research of British scientists applying for EU funding.

FinancingBelgium

20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.

Stock marketsFranceEU

19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.

ResearchUK

18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.

M&AUKSwitzerland

13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.

R&DAustriaFrance

12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.

M&AFranceEU

07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.

Prenatal DiagnosticsEUUK

06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.

GenericsSpainGermanyEU

04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • DIAMYD MEDICAL -B- (S)5.70 SEK21.54%
  • QIAGEN NV (D)23.48 EUR12.29%
  • MOBERG PHARMA (S)44.10 SEK10.25%

FLOP

  • MOLOGEN (D)1.81 EUR-11.71%
  • NICOX (F)9.62 EUR-8.29%
  • SAREUM HOLDINGS (UK)0.72 GBP-6.49%

TOP

  • PROTHENA PLC (IE)55.05 USD57.5%
  • DIAMYD MEDICAL -B- (S)5.70 SEK37.3%
  • VERNALIS (UK)44.50 GBP31.9%

FLOP

  • MOLOGEN (D)1.81 EUR-38.4%
  • SANTHERA (CH)56.20 CHF-26.9%
  • EVOCUTIS (UK)0.04 GBP-20.0%

TOP

  • KARO BIO (S)33.00 SEK1962.5%
  • NICOX (F)9.62 EUR425.7%
  • SAREUM HOLDINGS (UK)0.72 GBP213.0%

FLOP

  • BB BIOTECH (D)44.83 EUR-84.6%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.80 SEK-78.2%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 29.07.2016